Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 1/2 1

Status

Recruiting 2Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Urinary Bladder Neoplasms 10Non-Muscle Invasive Bladder Neoplasms 6Peritoneal Neoplasms 3Colorectal Neoplasms 3Carcinoma, Transitional Cell 3Appendiceal Neoplasms 3Anus Neoplasms 2Urothelial Carcinoma of the Bladder 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Rectal Neoplasms 1Pseudomyxoma Peritonei 1Peritoneal Diseases 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Necrosis 1Male Urogenital Diseases 1HIV Infections 1Gastrointestinal Neoplasms 1Female Urogenital Diseases 1Anal Canal Carcinoma 1

Interventions

Gemcitabine 10Mitomycin 6Docetaxel 5erdafitinib 4durvalumab 4BCG Vaccine 4dodecyl maltoside 3Cystoscopy 3ALT-803 2viscum album peptide 1tremelimumab 1pirarubicin 1monalizumab 1hydroxycamptothecinum 1chondroitin sulfate, sodium hyaluronate drug combination 1Watchful Waiting 1Transurethral Resection of Bladder 1Patient Discharge 1Paclitaxel 1Mitozytrex 1Magnetic Resonance Spectroscopy 1Injections 1Hyaluronic Acid 1House Calls 1Home Care Services 1Epirubicin 1Drainage 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1Chondroitin Sulfates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Non-Muscle Invasive Bladder Neoplasms × Mitomycin × 90 days × Clear all
NCT06211764 2026-06-05

SunRISe-5

Janssen Research & Development, LLC

Phase 3 Active not recruiting
272 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-06-05

MoonRISe-3

Janssen Research & Development, LLC

Phase 3 Recruiting
220 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07424287 2026-06-02

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Not yet recruiting
236 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT02106572 2026-05-22

TIM

Abnoba Gmbh

Phase 3 Terminated
174 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05243550 2026-05-11

ENVISION

UroGen Pharma Ltd.

Phase 3 Active not recruiting
240 enrolled 20 charts 1 FDA
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06704191 2026-03-30

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Mayo Clinic

Phase 1/2 Recruiting
40 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡